دورية أكاديمية
Clinical applications of gene therapy for rare diseases: A review
العنوان: | Clinical applications of gene therapy for rare diseases: A review |
---|---|
المؤلفون: | Papaioannou, Ioannis, Owen, James S, Yáñez-Muñoz, Rafael J |
المصدر: | International Journal of Experimental Pathology (2023) (In press). |
بيانات النشر: | Wiley |
سنة النشر: | 2023 |
المجموعة: | University College London: UCL Discovery |
مصطلحات موضوعية: | CAR-T cells, adeno-associated virus vectors, antisense oligonucleotides, retrovirus vectors |
الوصف: | Rare diseases collectively exact a high toll on society due to their sheer number and overall prevalence. Their heterogeneity, diversity, and nature pose daunting clinical challenges for both management and treatment. In this review, we discuss recent advances in clinical applications of gene therapy for rare diseases, focusing on a variety of viral and non-viral strategies. The use of adeno-associated virus (AAV) vectors is discussed in the context of Luxturna, licenced for the treatment of RPE65 deficiency in the retinal epithelium. Imlygic, a herpes virus vector licenced for the treatment of refractory metastatic melanoma, will be an example of oncolytic vectors developed against rare cancers. Yescarta and Kymriah will showcase the use of retrovirus and lentivirus vectors in the autologous ex vivo production of chimeric antigen receptor T cells (CAR-T), licenced for the treatment of refractory leukaemias and lymphomas. Similar retroviral and lentiviral technology can be applied to autologous haematopoietic stem cells, exemplified by Strimvelis and Zynteglo, licenced treatments for adenosine deaminase-severe combined immunodeficiency (ADA-SCID) and β-thalassaemia respectively. Antisense oligonucleotide technologies will be highlighted through Onpattro and Tegsedi, RNA interference drugs licenced for familial transthyretin (TTR) amyloidosis, and Spinraza, a splice-switching treatment for spinal muscular atrophy (SMA). An initial comparison of the effectiveness of AAV and oligonucleotide therapies in SMA is possible with Zolgensma, an AAV serotype 9 vector, and Spinraza. Through these examples of marketed gene therapies and gene cell therapies, we will discuss the expanding applications of such novel technologies to previously intractable rare diseases. |
نوع الوثيقة: | article in journal/newspaper |
وصف الملف: | text |
اللغة: | English |
العلاقة: | https://discovery.ucl.ac.uk/id/eprint/10170190/1/Clinical%20applications%20of%20gene%20therapy%20for%20rare%20diseases%20%20A%20review.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10170190Test/ |
الإتاحة: | https://discovery.ucl.ac.uk/id/eprint/10170190/1/Clinical%20applications%20of%20gene%20therapy%20for%20rare%20diseases%20%20A%20review.pdfTest https://discovery.ucl.ac.uk/id/eprint/10170190Test/ |
حقوق: | open |
رقم الانضمام: | edsbas.F7A16960 |
قاعدة البيانات: | BASE |
الوصف غير متاح. |